Mona Lisa, a Robotic MRI & Ultrasound of the prostate is a Fusion Biopsy platform to target lesions of the prostate that is set to revolutionize prostate biopsy in patients with a clinical suspicion of prostate cancer. These patients are often referred by GPs for further investigations following an abnormal rectal exam and/or Prostate Specific Antigen (PSA) blood test. While a raised PSA may be attributed to multiple prostate conditions, prostate cancer should be suspected and needs to be ruled out.
Traditional assessment includes examination of the prostate by inserting a finger into the back passage (digital rectal examination) and taking prostate tissue samples randomly through the rectum with the aid of an ultrasound probe (Transrectal Ultrasound (TRUS) prostate biopsy). TRUS prostate biopsy have been shown to have a poor sensitivity of 48%, where over 50% of prostate cancer will be missed1. In addition, it has a 3% risk of infection (sepsis) which will require hospital admission for intravenous antibiotics.
At Lifecare, we are proud to offer state of the art work up for patients with a suspicion of prostate cancer. We offer multiparametric MRI (mpMRI) prior to performing prostate biopsy. This allows us to determine if a prostate has any areas suspicious for prostate cancer. This has been shown to improve the detection of clinically significant prostate cancer and reduce the over detection of low risk prostate cancer which should be managed conservatively.
In the event that prostate lesions (area suspected for cancer) are identified on mpMRI, the Mona Lisa targeted fusion prostate biopsy robot uses images from the mpMRI and fuses it with ultrasound images to improve accuracy and precision. This ensures a ‘GPS’ like guidance system to precisely obtain prostate tissue from only two skin punctures, instead of the rectum, which significantly decreases the rate of sepsis, and minimizes trauma to the rectum.
Such an approach allows a precise targeting of the prostate resulting in the identification of 93% of significant prostate cancer1. Accurate staging and grading of patients with prostate cancer is crucial as this will influence decisions relating to further management of the cancer.
Previously, patients would have to travel to countries such as Australia, the UK and Singapore to have the robotic prostate biopsy procedure.
This revolutionary technology is now available for the first time in Malaysia at Life Care Diagnostic Medical Center.
Life Care Diagnostics Medical Centre, established in 2005, is a premiere medical facility strategically located in Bangsar South, Kuala Lumpur. Life Care provides health screening services with the aim of improving the health of patients based on their wellness philosophy of early diagnosis, pre-symptomatic disease detection and disease prevention.